{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:09:40Z","timestamp":1790820580111,"version":"4.1.0"},"reference-count":31,"publisher":"Society of Nuclear Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.2967\/jnumed.122.265355","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T11:50:12Z","timestamp":1684410612000},"page":"1076-1082","source":"Crossref","is-referenced-by-count":43,"title":["Evaluation of\n                    <sup>134<\/sup>\n                    Ce\/\n                    <sup>134<\/sup>\n                    La as a PET Imaging Theranostic Pair for\n                    <sup>225<\/sup>\n                    Ac \u03b1-Radiotherapeutics"],"prefix":"10.2967","volume":"64","author":[{"given":"Kondapa Naidu","family":"Bobba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil P.","family":"Bidkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Meher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Wadhwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchi","family":"Dhrona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Sorlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Bidlingmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becka","family":"Shuere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngho","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry F.","family":"VanBrocklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Flavell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"2023063006250748000_64.7.1076.1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"key":"2023063006250748000_64.7.1076.2","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1002\/cmdc.202100135","article-title":"Recent advances in radiometals for combined imaging and therapy in cancer","volume":"16","author":"Herrero \u00c1lvarez","year":"2021","journal-title":"ChemMedChem."},{"key":"2023063006250748000_64.7.1076.3","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","article-title":"Targeted alpha therapy, an emerging class of cancer agents: a review","volume":"4","author":"Parker","year":"2018","journal-title":"JAMA Oncol."},{"key":"2023063006250748000_64.7.1076.4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/cancers13040779","article-title":"Preclinical and clinical status of PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer","volume":"13","author":"Juzeniene","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2023063006250748000_64.7.1076.5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088239"},{"key":"2023063006250748000_64.7.1076.6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An overview of targeted alpha therapy with 225actinium and 213bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr Radiopharm."},{"key":"2023063006250748000_64.7.1076.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"2023063006250748000_64.7.1076.8","doi-asserted-by":"crossref","first-page":"11671","DOI":"10.1038\/s41598-019-48298-8","article-title":"The in\u00a0vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier","volume":"9","author":"de Kruijff","year":"2019","journal-title":"Sci Rep."},{"key":"2023063006250748000_64.7.1076.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.255794"},{"key":"2023063006250748000_64.7.1076.10","doi-asserted-by":"crossref","first-page":"584\u2013590","DOI":"10.2967\/jnumed.121.262459","article-title":"First in\u00a0vivo and phantom imaging of cyclotron-produced 133La as a theranostic radionuclide for 225Ac and 135La","volume":"63","author":"Nelson","year":"2022","journal-title":"J Nucl Med."},{"key":"2023063006250748000_64.7.1076.11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41557-020-00598-7","article-title":"Developing the 134Ce and 134La pair as companion positron emission tomography diagnostic isotopes for 225Ac and 227Th radiotherapeutics","volume":"13","author":"Bailey","year":"2021","journal-title":"Nat Chem."},{"key":"2023063006250748000_64.7.1076.12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1088\/0031-9155\/47\/4\/305","article-title":"Production, PET performance and dosimetric considerations of 134Ce\/134La, an Auger electron and positron-emitting generator for radionuclide therapy","volume":"47","author":"Lubberink","year":"2002","journal-title":"Phys Med Biol."},{"key":"2023063006250748000_64.7.1076.13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.nucmedbio.2022.04.007","article-title":"Evaluation of 134Ce as a PET imaging surrogate for antibody drug conjugates incorporating 225Ac","volume":"110-111","author":"Bailey","year":"2022","journal-title":"Nucl Med Biol."},{"key":"2023063006250748000_64.7.1076.14","doi-asserted-by":"crossref","first-page":"10429","DOI":"10.1021\/jacs.1c05339","article-title":"Py-macrodipa: a Janus chelator capable of binding medicinally relevant rare-earth radiometals of disparate sizes","volume":"143","author":"Hu","year":"2021","journal-title":"J Am Chem Soc."},{"key":"2023063006250748000_64.7.1076.15","doi-asserted-by":"crossref","first-page":"14712","DOI":"10.1002\/anie.201709532","article-title":"An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy","volume":"56","author":"Thiele","year":"2017","journal-title":"Angew Chem Int Ed Engl."},{"key":"2023063006250748000_64.7.1076.16","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41391-021-00349-w","article-title":"Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"24","author":"Satapathy","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2023063006250748000_64.7.1076.17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","article-title":"225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023063006250748000_64.7.1076.18","doi-asserted-by":"crossref","first-page":"e121497","DOI":"10.1172\/jci.insight.121497","article-title":"Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer","volume":"3","author":"Su","year":"2018","journal-title":"JCI Insight."},{"key":"2023063006250748000_64.7.1076.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3310"},{"key":"2023063006250748000_64.7.1076.20","doi-asserted-by":"crossref","unstructured":"Bidkar AP Wang S Bobba KN . Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy. Clin Cancer Res. March 14, 2023 [Epub ahead of print].","DOI":"10.1158\/1078-0432.CCR-22-3291"},{"key":"2023063006250748000_64.7.1076.21","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S0969-8051(22)00140-8","article-title":"Influence of short PEG linkers on biodistribution of 225Ac-macropa-YS5, an immunoconjugate for treating CD46 expressing cancer [abstract]","volume":"108\u2013109(suppl)","author":"Bobba","year":"2022","journal-title":"Nucl Med Biol."},{"key":"2023063006250748000_64.7.1076.22","doi-asserted-by":"crossref","unstructured":"Li J Huang T Hua J . CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment. bioRxiv website. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.10.14.512321v1. Published October 18, 2022. Accessed April 13, 2023.","DOI":"10.1186\/s13046-023-02636-x"},{"key":"2023063006250748000_64.7.1076.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.161299"},{"key":"2023063006250748000_64.7.1076.24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4103\/ijnm.ijnm_200_20","article-title":"In-house preparation and quality control of Ac-225 prostate-specific membrane antigen-617 for the targeted alpha therapy of castration-resistant prostate carcinoma","volume":"36","author":"Thakral","year":"2021","journal-title":"Indian J Nucl Med."},{"key":"2023063006250748000_64.7.1076.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4039(01)00392-6"},{"key":"2023063006250748000_64.7.1076.26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3390\/pharmaceutics14050939","article-title":"Improved characteristics of RANKL immuno-PET imaging using radiolabeled antibody Fab fragments","volume":"14","author":"Dewulf","year":"2022","journal-title":"Pharmaceutics."},{"key":"2023063006250748000_64.7.1076.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1485"},{"key":"2023063006250748000_64.7.1076.28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11307-015-0908-7","article-title":"Targeting PSMA with a Cu-64 labeled phosphoramidate inhibitor for PET\/CT imaging of variant PSMA-expressing xenografts in mouse models of prostate cancer","volume":"18","author":"Nedrow","year":"2016","journal-title":"Mol Imaging Biol."},{"key":"2023063006250748000_64.7.1076.29","doi-asserted-by":"crossref","first-page":"6148357","DOI":"10.1155\/2016\/6148357","article-title":"In vivo radionuclide generators for diagnostics and therapy","volume":"2016","author":"Edem","year":"2016","journal-title":"Bioinorg Chem Appl."},{"key":"2023063006250748000_64.7.1076.30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fmed.2017.00098","article-title":"Neodymium-140 DOTA-LM3: evaluation of an in\u00a0vivo generator for PET with a non-internalizing vector","volume":"4","author":"Severin","year":"2017","journal-title":"Front Med (Lausanne)."},{"key":"2023063006250748000_64.7.1076.31","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1038\/s41598-022-07147-x","article-title":"PET in\u00a0vivo generators 134Ce and 140Nd on an internalizing monoclonal antibody probe","volume":"12","author":"Severin","year":"2022","journal-title":"Sci Rep."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.265355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T09:29:26Z","timestamp":1688117366000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.265355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,6,30]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.2967\/jnumed.122.265355"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.265355","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]}}}